In the BioHarmony Drug Report Database

"Preview" Icon

Hydrocortisone probutate

Pandel, Alkindi, Efmody, Plenadren (hydrocortisone probutate) is a small molecule pharmaceutical. Hydrocortisone probutate was first approved as Pandel on 1997-02-28. It is used to treat adrenal insufficiency, congenital adrenal hyperplasia, contact dermatitis, facial dermatoses, and foot dermatoses amongst others in the USA. It has been approved in Europe to treat adrenal insufficiency and congenital adrenal hyperplasia.

 

Trade Name

 

Alkindi, Efmody, Plenadren
 

Common Name

 

hydrocortisone probutate
 

ChEMBL ID

 

CHEMBL1200953
 

Indication

 

adrenal insufficiency, congenital adrenal hyperplasia, contact dermatitis, facial dermatoses, foot dermatoses, hand dermatoses, hemorrhoids, inflammation, leg dermatoses, pruritus ani, rheumatic diseases, scalp dermatoses, shock, status asthmaticus, ulcerative colitis
 

Drug Class

 

Cortisone derivatives

Image (chem structure or protein)

Hydrocortisone probutate structure rendering